Skip to main content
logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.71
+0.32 (1.65%)
At close: May 29, 2026, 4:00 PM EDT
19.80
+0.09 (0.46%)
After-hours: May 29, 2026, 7:52 PM EDT

Monte Rosa Therapeutics Revenue

Monte Rosa Therapeutics had revenue of $4.21M in the quarter ending March 31, 2026, a decrease of -95.04%. This brings the company's revenue in the last twelve months to $42.95M, down -73.07% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth.

Revenue (ttm)
$42.95M
Revenue Growth
-73.07%
P/S Ratio
38.77
Revenue / Employee
$229,695
Employees
187
Market Cap
1.67B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025123.67M48.05M63.54%
Dec 31, 202475.62M--
Dec 31, 2023---
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Novavax596.34M
Innoviva420.69M
AnaptysBio232.39M
Nuvation Bio143.05M
Vir Biotechnology65.50M
Precigen31.60M
Generate Biomedicines30.30M
Capricor Therapeutics11.13M
Revenue Rankings

GLUE News

More News